Sep 15, 2020 / 05:15PM GMT
Tejas Rajeev Savant - Morgan Stanley, Research Division - Equity Analyst
Hello, everyone. Good afternoon. Thanks for joining us today on day 2 of our healthcare conference. I'm Tejas Savant, and I cover the life science tools and diagnostics sector here at Morgan Stanley. I'm delighted to have Adaptive Biotechnologies join us today. And representing the company is Chad Robins, CEO. Thanks for joining us, Chad.
Before we begin, I just want to read a quick disclaimer. Please note the webcast is for Morgan Stanley's clients and appropriate Morgan Stanley employees only. The webcast is not for members of the press. If you are with the press, please disconnect and reach out separately. For important disclosures, please see morganstanley.com/researchdisclosures. And if you have any questions, please feel free to reach out to your sales rep.
Questions and Answers:
Tejas Rajeev Savant - Morgan Stanley, Research Division - Equity AnalystSo with that, Chad, I mean, maybe just to kick things off, can you just go over, in your mind, sort of the value of the